Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04576156
Title A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Geron Corporation
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | BRA | BGR | BEL | AUT | AUS | ARG


No variant requirements are available.